These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 25960329)
1. Low-density lipoprotein peptide-combined DNA nanocomplex as an efficient anticancer drug delivery vehicle. Zhang N; Tao J; Hua H; Sun P; Zhao Y Eur J Pharm Biopharm; 2015 Aug; 94():20-9. PubMed ID: 25960329 [TBL] [Abstract][Full Text] [Related]
2. Charge-conversional and reduction-sensitive poly(vinyl alcohol) nanogels for enhanced cell uptake and efficient intracellular doxorubicin release. Chen W; Achazi K; Schade B; Haag R J Control Release; 2015 May; 205():15-24. PubMed ID: 25445693 [TBL] [Abstract][Full Text] [Related]
3. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts. Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560 [TBL] [Abstract][Full Text] [Related]
4. Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery. Zhang C; Zhao L; Dong Y; Zhang X; Lin J; Chen Z Eur J Pharm Biopharm; 2010 Sep; 76(1):10-6. PubMed ID: 20472060 [TBL] [Abstract][Full Text] [Related]
5. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice. Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771 [TBL] [Abstract][Full Text] [Related]
6. Effects of lipid composition on the properties of doxorubicin-loaded liposomes. Sakai-Kato K; Nanjo K; Kawanishi T; Okuda H; Goda Y Ther Deliv; 2015 Jul; 6(7):785-94. PubMed ID: 26228772 [TBL] [Abstract][Full Text] [Related]
7. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity. Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094 [TBL] [Abstract][Full Text] [Related]
8. Nanoparticle delivery strategies to target doxorubicin to tumor cells and reduce side effects. Wang Y; Wei X; Zhang C; Zhang F; Liang W Ther Deliv; 2010 Aug; 1(2):273-87. PubMed ID: 22816133 [TBL] [Abstract][Full Text] [Related]
9. Green-step assembly of low density lipoprotein/sodium carboxymethyl cellulose nanogels for facile loading and pH-dependent release of doxorubicin. He L; Liang H; Lin L; Shah BR; Li Y; Chen Y; Li B Colloids Surf B Biointerfaces; 2015 Feb; 126():288-96. PubMed ID: 25576811 [TBL] [Abstract][Full Text] [Related]
10. DNA decorated Cu Liang S; Xie Z; Wei Y; Cheng Z; Han Y; Lin J Dalton Trans; 2018 Jun; 47(24):7916-7924. PubMed ID: 29790525 [TBL] [Abstract][Full Text] [Related]
11. Improved drug targeting of cancer cells by utilizing actively targetable folic acid-conjugated albumin nanospheres. Shen Z; Li Y; Kohama K; Oneill B; Bi J Pharmacol Res; 2011 Jan; 63(1):51-8. PubMed ID: 21035550 [TBL] [Abstract][Full Text] [Related]
12. Oxidized phospholipid based pH sensitive micelles for delivery of anthracyclines to resistant leukemia cells in vitro. Wang Y; Chen L; Ding Y; Yan W Int J Pharm; 2012 Jan; 422(1-2):409-17. PubMed ID: 22037443 [TBL] [Abstract][Full Text] [Related]
13. Design and evaluation of clickable gelatin-oleic nanoparticles using fattigation-platform for cancer therapy. Meghani NM; Amin HH; Park C; Park JB; Cui JH; Cao QR; Lee BJ Int J Pharm; 2018 Jul; 545(1-2):101-112. PubMed ID: 29698822 [TBL] [Abstract][Full Text] [Related]
14. Enhanced cytotoxicity of core modified chitosan based polymeric micelles for doxorubicin delivery. Ye YQ; Chen FY; Wu QA; Hu FQ; Du YZ; Yuan H; Yu HY J Pharm Sci; 2009 Feb; 98(2):704-12. PubMed ID: 18563810 [TBL] [Abstract][Full Text] [Related]
15. Cellular delivery of doxorubicin mediated by disulfide reduction of a peptide-dendrimer bioconjugate. Burns KE; Delehanty JB Int J Pharm; 2018 Jul; 545(1-2):64-73. PubMed ID: 29709616 [TBL] [Abstract][Full Text] [Related]
16. Comparative studies of polyethylenimine-doxorubicin conjugates with pH-sensitive and pH-insensitive linkers. Dong DW; Tong SW; Qi XR J Biomed Mater Res A; 2013 May; 101(5):1336-44. PubMed ID: 23065848 [TBL] [Abstract][Full Text] [Related]
17. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model. Wong HL; Rauth AM; Bendayan R; Wu XY Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986 [TBL] [Abstract][Full Text] [Related]
18. In vivo studies of octreotide-modified N-octyl-O, N-carboxymethyl chitosan micelles loaded with doxorubicin for tumor-targeted delivery. Zou A; Chen Y; Huo M; Wang J; Zhang Y; Zhou J; Zhang Q J Pharm Sci; 2013 Jan; 102(1):126-35. PubMed ID: 23073894 [TBL] [Abstract][Full Text] [Related]
19. Low density lipoprotein peptide conjugated submicron emulsions for combating prostate cancer. Sun P; Zhang N; Hua H; Liang Q; Zhang X; Sun Q; Zhao Y Biomed Pharmacother; 2017 Feb; 86():612-619. PubMed ID: 28027537 [TBL] [Abstract][Full Text] [Related]
20. Anticancer activity of galactoxyloglucan polysaccharide-conjugated doxorubicin nanoparticles: Mechanistic insights and interactome analysis. Joseph MM; Aravind SR; George SK; Raveendran Pillai K; Mini S; Sreelekha TT Eur J Pharm Biopharm; 2015 Jun; 93():183-95. PubMed ID: 25864443 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]